Company intelligence / Profile preview

Kangzhong (Beijing) Biotechnology

Beijing Shi, Beijing, China

Ownership: Private
Development stage: Other

Overview

Kangzhong (Beijing) Biotechnology focuses on research, manufacture, and distribution of vaccines against human infectious diseases as well as diagnostic reagents and antibody-based drugs. Its most advanced program is a Phase IIb clinical trial evaluating the safety/tolerability of a Mycobacterium tuberculosis antigen ("D-EC") skin test in children/adolescents and elderly populations. The company also works in neoplasm-related indications but details are limited.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Prophylactic vaccineNanobodyAntibody-based pharmaceuticalsDiagnostic agent
Industry: Biotech

Beyond the preview

Go deeper on Kangzhong (Beijing) Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kangzhong (Beijing) Biotechnology.

Explore the full profile